SCHEMBL427555

SCHEMBL427555

CC1COCN1C(=O)n1cnc(-c2ccccc2)c1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.46
CES2 O00748 1/20 0.39
MTOR P42345 6/20 0.36
ALOX5AP P20292 1/20 0.35
FEN1 P39748 1/20 0.35
ALDH1A1 P00352 3/20 0.34
PHGDH O43175 1/20 0.34
USP19 O94966 2/20 0.34
MAPK1 P28482 2/20 0.33
KDM4E B2RXH2 1/20 0.33
LMNA P02545 1/20 0.33
HPGD P15428 1/20 0.33
HTT P42858 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
GSK3A P49840 2/20 0.33
DAGLA Q9Y4D2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL425924 0.85 FAAH (0.46) FAAHCES2ALDH1A1USP19KDM4E
SCHEMBL427146 0.84 ALOX5AP (0.39) MTORALOX5APFEN1
SCHEMBL424570 0.79 FAAH (0.44) FAAHCES2ALDH1A1USP19MAPK1
SCHEMBL427480 0.76 FAAH (0.46) FAAHCES2ALDH1A1USP19MAPK1
SCHEMBL17460215 0.75 FAAH (0.47) FAAH
SCHEMBL424684 0.73 ALDH1A1 (0.45) FAAHALDH1A1KDM4ELMNAHTT
SCHEMBL425743 0.73 FAAH (0.43) FAAHCES2ALDH1A1USP19KDM4E
SCHEMBL426612 0.73 ALDH1A1 (0.51) ALDH1A1KDM4ELMNAHPGDHTT
SCHEMBL19294003 0.72 CHRNA7 (0.46) FAAHCES2PHGDH
SCHEMBL427552 0.72 NPSR1 (0.39) ALDH1A1MAPK1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
WO-2010074588-A2 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2010-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 FAAH 1/4885CES2 62/4885MTOR 2894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.